News
)
15 November 2022
Successful participation of VIVEbiotech in international events in 2022
VIVEbiotech has successfully participated in 7 international events during 2023.
)
21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a further three years.
)
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
)
2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Destacadas
)
December 4, 2024
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities)
October 25, 2024
VIVEbiotech publishes new research paper)
October 24, 2024
Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting)
October 10, 2024
VIVEbiotech participates one more year in the Innovative Therapies Days)
October 8, 2024
VIVEbiotech participates in Cell & Gene Meeting on the Mesa)
September 18, 2024
Q&A in GEN with Natalia Elizalde)
September 11, 2024
VIVEbiotech participates in Advanced Therapies Europe)
September 9, 2024
VIVEbiotech achieves renewal of CIR certification)
August 28, 2024
New scientific paper in Viruses)
August 23, 2024
Enhancing global access to advanced therapies: VIVEbiotech’s role in optimizing production and reducing costs